Immuneering Corporation Profile Avatar - Palmy Investing

Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorect…

Biotechnology
US, Cambridge [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Immuneering Corporation has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Immuneering Corporation can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Immuneering Corporation.

End of IMRX's Analysis
CIK: 1790340 CUSIP: 45254E107 ISIN: US45254E1073 LEI: - UEI: -
Secondary Listings
IMRX has no secondary listings inside our databases.